PolyNovo

Historical price data

PolyNovo is a publicly traded medical technology company focused on addressing unmet needs in surgical reconstruction and wound care. Its core innovation is the NovoSorb platform, a family of bioresorbable polyurethane polymers designed to integrate with tissue and degrade safely. The company has achieved significant commercial success with its first product, NovoSorb BTM, and is actively expanding its product portfolio and geographic reach.

NovoSorb, a proprietary family of synthetic, biodegradable polyurethane polymers that can be formulated into bioresorbable scaffolds for tissue integration and regeneration.

Total raised: $36M

PolyNovo competes against biologic grafts (e.g., AlloDerm) and other synthetic meshes in hernia/breast surgery, and against other dermal substitutes (e.g., Integra) in wound care. Its primary differentiation is its proprietary, fully synthetic, and resorbable NovoSorb polymer technology, which offers consistent performance, reduced infection risk, and cost advantages over biologic competitors.